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Chimeric antigen receptor (CAR) T cells have been strikingly successful in the treatment of hematologic cancers 1 but have not been effective against solid tumors thus far. 2 A recent report by Samaha and colleagues 3 presents a preclinical version of CAR T-cell therapy for a solid tumor, glioblastoma. These investigators engineered a CAR T cell to express a homing molecule (an adhesion molecule), which allows it to tether to and then migrate through the endothelial cells that make up the vasculature perfusing a mouse model of glioblastoma. Their approach is built on the detailed study of tumor endothelial phenotypes and adhesion pathways that affect T-cell endothelial transmigration.
Complications of natalizumab, a drug targeting an integrin adhesion molecule used in the treatment of multiple sclerosis, have taught us that immune cells normally cross the blood-brain barrier and carry out surveillance of the central nervous system (CNS) for viral infection. 4 Samaha et al. started with the observation that the endothelium of the vasculature that supplies glioblastomas down-regulates ligands of the integrin adhesins, which are expressed by effector T cells and are pivotal to most mechanisms governing access to the CNS, but up-regulates an alternative homing ligand, the activated leukocyte cell adhesion molecule (ALCAM), otherwise known as CD166.
3 ALCAM binds to a transmembrane receptor on T cells, CD6, which facilitates T-cell migration across the blood-brain barrier into the CNS. Samaha et al. found that the forced expression of an engineered CD6-based homing system by CAR T cells effectively steered these engineered cells into the tumor and improved control of glioblastoma in an orthotopic model. The study supports a new phase of engineering of CAR T cells and provides lessons that may be useful in the design of future immunotherapies. 3 devised a CD6-based homing system (Panel B) in which CD6 was engineered to lack the two N-terminal domains that are normally present and that might hinder its binding to ALCAM and to contain up to five copies (5HS shown) of the ALCAM-binding domain (red rectangles). Human epidermal growth factor receptor 2 (HER2) is the molecular target on the tumor cells that is targeted by the chimeric antigen receptor (CAR). First, Samaha et al. modified CD6 to work as a homing system. The CD6 protein normally contains three domains, called scavenger receptor cysteine-rich (SRCR) domains, but only one of these domains, the one that is proximal to the transmembrane region, binds ALCAM. The authors reasoned that if they could engineer a CD6 molecule that presented multiple binding domains to ALCAM, they could increase the adhesion of the T cell to the vascular endothelium and thus initiate the next wave of adhesion necessary for transmigration. The rationale for removal of the two N-terminal SRCR domains was based not only on their lack of direct interaction with ALCAM but also on the observation that their presence in native CD6 might hinder ligand recognition. They created three different new versions of CD6, with one, three, and five copies of the membrane proximal SRCR domain of native CD6 (see Fig. 1 for a depiction of one of these) and tested these in orthotopic mouse models of glioblastoma and medulloblastoma. They observed that T cells that expressed the homing system have improved homing to these tumors when injected intravenously. The process was selective for tumor endothelium, with no A CAR T cell that is engineered with both an HER2-specific CAR and an ALCAM-specific homing system (5HS) can attach and extravasate in tumor vascular beds characterized by a high level of ALCAM (shown) and low levels of intercellular adhesion molecule 1 and vascular-cell adhesion molecule (not shown). This process requires inside-out signaling from the homing system. Once the CAR T cell is within the tumor, engagement of the CAR by its target on the tumor surface enables the killing of tumor cells (lightning bolt). The homing system, which has done its job, is not needed for the killing process. CAR T cells that lack the homing system will tend to flow through the tumor vasculature with blood flow (red arrow) and not enter the tumor. Extravasation detection of infiltration into normal brain tissue, and preferential recruitment of engineered as compared with normal T cells was not observed in kidney, spleen, and lungs in these mice. Second, the authors took advantage of a remarkable natural feature of the cytoplasmic region of the CD6 molecule to enhance transendothelial migration, through its "inside-out" activation of T-cell integrins, including lymphocyte function-associated antigen 1 (LFA-1). The ligands of LFA-1, expressed on the vascular endothelial cells of glioblastomas, are suppressed but still present. One of these ligands is intercellular adhesion molecule 1 (ICAM-1) .
The engagement of the engineered CD6 homing receptors by up-regulated ALCAM resulted sequentially in the activation of LFA-1, its highaffinity binding to ICAM-1, changes in the shape of the CAR T cell to increase contact with the endothelium, and then transmigration through the endothelium and into the tumor. Interaction with the endothelium did not require engagement by the CAR. The authors verified the effect of this homing system in promoting CAR T-cell interaction with tumor vasculature, entry into the tumor, and improved tumor control and longer survival in the mouse model of glioblastoma (Fig. 2) . Thus, the CD6 cytoplasmic domain will probably be a useful module in engineering other homing systems with different targets. CD6 has the longest cytoplasmic region of the noncatalytic tyrosine phosphorylated immunoreceptors. Complementary to engineering of the extracellular region, development of homing systems may involve isolation of sequences in the CD6 cytoplasmic tail that are crucial for its activating effects. 5 The design of this homing system was based on fundamental observations made in the context of understanding how cell-surface receptors regulate the immune system at a molecular level. There are many potential barriers to the function of CAR T cells in solid tumors, but similar rational approaches may lead in the future to a tool kit to engineer designer CAR T cells from safety-tested modules that can be implemented in combination to target molecular phenotypes of different solid tumors.
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